Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Fate Therapeutics, Inc.NASDAQ: FATE

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $2.92M fell 12.5% year over year, ahead of the -28.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at -12.3% a year.

Context

  • Depreciation & amortization amounted to 139.9% of revenue in FY2025, up 0.7 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -12.5% holds above the trailing-twelve-month pace of -28.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.92M-4.7% QoQ
Last fiscal yearDec 2025
$9.3M-51.0% YoY
LTMMar 2026
$12.49M-28.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.5%——
1 year-51.0%——
3-year CAGR-12.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
9.3M USD
Year-over-year change
-51.0%
4-year CAGR
+12.3%

Depreciation & Amortization vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.5% is the 7th highest of 10, against a peer median of -3.9%.
  • Depreciation & amortization amounts to 197.7% of revenue for FATE, versus a peer median of 28.9%.
FATE Competitors
Depreciation & Amortization for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$12.49M USD-28.5%-12.3%197.7%
NKTXNkarta, Inc.LTM Mar 2026$9.23M USD+0.4%+51.6%—
ALECAlector, Inc.LTM Mar 2026$8.8M USD+4.8%+4.5%47.8%
PEPGPepGen Inc.LTM Mar 2026$3.2M USD-40.7%+41.5%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M USD-3.9%-18.4%—
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF+9.7%-3.5%—
VORVor Biopharma Inc.LTM Mar 2026$2.09M USD-38.7%-31.4%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$1.67M USD-6.4%+8.9%10.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$248K USD-57.2%-46.1%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$185K USD+3.4%+2.9%—
Peer median (excluding FATE) —-3.9%+2.9%28.9%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.